SUPN compared with LGND: revenue, margins and what each company keeps, and the suppliers and customers both name

SUPNSupernus Pharmaceuticals, Inc.

Mkt capRevenueRevenue

LGNDLigand Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

SUPNSupernus Pharmaceuticals, Inc.

LGNDLigand Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SUPN

0 of 2at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26—▲+0.19%—

Oct 20 '26—▲+3.49%—

Aug 3 '26±11.3%▲+3.07%×0.27

Q2 FY26±11.3%▲+0.53%×0.04

LGND

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.5%▼−0.45%×0.07

Q2 FY26±7.1%▼−0.80%×0.11

= impliedSUPN realized, solidLGND realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedspan: SUPN 99d · LGND 245dSource: market data

May 7 '26

±6.2%

▼−9.55%

×1.55

Q1 FY26±7.8%▲+2.50%×0.32

SUPNSupernus Pharmaceuticals, Inc.

41.94▲+0.24%

Mkt cap$2.4BRevenue$219MQ2 FY26Revenue$719MFY25

LGNDLigand Pharmaceuticals Inc

312.00▼−3.33%

Regular sessionNov 2 '26

Mkt cap$6.5BRevenue$79MQ3 FY26Revenue$268MFY25

Compare

Regular sessionNov 2 '26

SUPNSupernus Pharmaceuticals, Inc.

LGNDLigand Pharmaceuticals Inc

41.94▲+0.24%

Price

312.00▼−3.33%

$2.4B

Mkt cap

$6.5B

Q2 FY26$219M

Revenue

$79MQ3 FY26

FY25$719M

Revenue

$268MFY25

SUPN41.94▲+0.24%vsLGND312.00▼−3.33%Regular sessionNov 2 '26